CurrentCapital BluecrossPolicy MP 2.359

Analysis of MGMT Promoter Methylation in Malignant Gliomas

This policy governs medical necessity and coverage considerations for testing methylation of the MGMT gene promoter in patients with high-grade malignant gliomas to inform use of temozolomide or radiotherapy.

Policy Summary

PayerCapital Bluecross

PolicyAnalysis of MGMT Promoter Methylation in Malignant Gliomas

Policy CodePolicy MP 2.359

Change TypeNo material changes

Effective DateJan 1, 2024

Next Review Date

Key ActionSubmit clinical documentation showing high-grade malignant glioma, candidacy for temozolomide or radiotherapy, and that methylation results will be used to direct therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

40-50%Approx. GBMs with MGMT methylation

17,000Approx. annual new cases (US)

81287Covered procedure code

Adopted from BCBSAOrigination

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical necessity criteria

Methylation analysis of the MGMT promoter is medically necessary when ALL of the following criteria are met:

MGMT testing medical necessity criteria: Tumor type consistent with high-grade malignant glioma (e.g., glioblastoma multiforme, anaplastic astrocytoma);

From policy I. POLICY

MGMT testing medical necessity criteria: Patient is a candidate for temozolomide therapy or radiotherapy;

From policy I. POLICY

MGMT testing medical necessity criteria: Methylation results will be used to direct therapy choices.

From policy I. POLICY

Investigational indications

Not covered / investigational when the above criteria are not met:

Investigational uses: MGMT promoter methylation analysis is investigational in situations that do not meet the specified medical necessity criteria due to insufficient evidence of benefit in those settings.

From policy I. POLICY and SUMMARY OF EVIDENCE

Status / Historical coverage

policy_status: Policy MP 2.359 has been retired as of 08/03/2023

Retirement recorded in policy history; original coverage criteria text present in earlier sections

The existence of this medical policy does not guarantee that the described service is a covered benefit under every member's health benefit plan. Benefit determinations depend on the specific terms of the member's contract and plan design. Members and providers should consult the applicable health benefit plan language or contact Capital Blue Cross to determine coverage, exclusions, benefit limits, and preauthorization requirements.

Within the extracted policy text there are no additional explicit exclusion conditions listed beyond the standard benefit-variation notice. The policy history and coding reviews referenced in the document do not provide specific exclusion clauses in the extracted chunks.

MGMT promoter methylation testing is considered investigational (not medically necessary) when the medical necessity criteria are not all met. Specifically, testing may be investigational if the patient does not have a tumor type consistent with a high-grade malignant glioma (e.g., glioblastoma multiforme or anaplastic astrocytoma), is not a candidate for temozolomide therapy or radiotherapy, or when the methylation results will not be used to direct therapy choices. The policy states there is insufficient evidence to support benefit in situations that do not meet these criteria.

No explicit additional statements labeled "not medically necessary" appear in the extracted chunks beyond the investigational statement tied to unmet criteria and the policy retirement history noted in the policy history section.

Coding

Covered when medically necessary: Procedure CodesCPTCovered

81287

MGMT (O6-methylguanine DNA methyltransferase) promoter methylation analysis

Relevant ICD-10 Diagnosis CodesICD-10

C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified

Coding review history notedmixed

No codes listed

Coding

Coding thresholdsNone specified

Provider Actions & Requirements

Note

Retirement Notice

This policy was retired effective 08/03/2023. Providers should verify current coverage policies and benefit plan language for members, as retirement of this policy may affect prior authorization or coverage decisions.

Retirement date: 08/03/2023
Check member's health benefit plan for current coverage information

Documentation Required

Required Documentation for Medical Necessity

Clinical documentation must support medical necessity. Include pathology-confirmed tumor type consistent with high-grade malignant glioma (e.g., glioblastoma multiforme, anaplastic astrocytoma), documentation that the patient is a candidate for temozolomide therapy or radiotherapy, and a statement that MGMT promoter methylation results will be used to direct therapy choices.

Required diagnosis documentation (e.g., pathology report) demonstrating high-grade malignant glioma
Clinical notes indicating candidacy for temozolomide (TMZ) and/or radiotherapy (RT)
Statement of intended use of MGMT methylation results to guide treatment

Documentation Required

Expected Test Methodology Documentation

Report test methods and validation details. Documentation should state the assay methodology (for example, PCR-based methods or quantitative alternatives), specimen type (formalin-fixed paraffin-embedded tumor tissue), and laboratory validation demonstrating reliability and reproducibility.

Specify assay type (e.g., PCR-based, restriction-coupled qPCR, pyrosequencing)
Document specimen source and handling (FFPE tumor tissue)
Provide laboratory validation data or reference demonstrating assay reliability/reproducibility

Prior Authorization

Prior Authorization May Vary by Product

Prior authorization requirements vary by product and the member's benefit plan. Providers should consult the member's specific health benefit plan or contact Capital Blue Cross to determine if preauthorization is required for MGMT promoter methylation testing.

Prior authorization may be required depending on product and plan
FEP PPO: refer to FEP Medical Policy Manual for guidance

Covered Regimens and Clinical Use

Regimen	Indication / patient selection	Coverage stance
Temozolomide (TMZ) combined with radiotherapy	Newly diagnosed high-grade malignant glioma (e.g., glioblastoma multiforme, anaplastic astrocytoma); patient is a candidate for temozolomide and radiotherapy	Covered with criteria
Temozolomide (TMZ) alone	Select older patients (>70 years) with good performance status and methylated MGMT promoter; option when hypofractionated RT is an alternative	Covered with criteria
Hypofractionated radiotherapy (RT) alone	Select older patients (>70 years) depending on performance status and MGMT promoter methylation status; considered when TMZ may be less suitable	Covered with criteria

Regimen / trial context	Relevance of MGMT methylation	Coverage stance
Radiotherapy with concomitant and adjuvant temozolomide (EORTC‑NCIC / Stupp regimen)	MGMT promoter methylation is predictive of greater benefit from alkylating agents such as TMZ; TMZ + RT remains standard care for most patients	Informational / supports coverage when medical-necessity criteria met
Temozolomide alone versus radiotherapy alone in elderly patients (NOA‑08, Nordic trials)	Trials indicate MGMT methylation helps guide choice between TMZ alone and radiotherapy (including hypofractionated RT) in older patients	Informational / supports coverage decisions when criteria met

Line of Therapy

first-line

Use with standard therapy: MGMT testing is used to inform use of temozolomide with radiotherapy (standard of care) and in select older patients to guide choice between hypofractionated radiotherapy or temozolomide alone.

From Treatment and Summary of Evidence

first-line

line_of_therapy_note: Referenced trials include initial therapy studies of radiotherapy with concomitant and adjuvant temozolomide, and trials addressing elderly-patient regimens where MGMT status informed treatment choice.

From cited clinical trials and references

Biomarker Requirements

Biomarker requirement

Required biomarkerMGMT promoter methylation — testing is required to predict response to alkylating chemotherapy (e.g., temozolomide) and to inform therapy choice for high‑grade malignant gliomas.

Biomarker requirement

Required biomarkerIDH1 variant — reported to modulate prognostic and predictive interpretation of MGMT methylation status; combination of IDH1 mutation and MGMT methylation predicts survival better than either alone.

MGMT promoter methylation — additional references

Supporting evidenceMultiple reviews and meta-analyses discuss MGMT testing challenges and prognostic/predictive value (e.g., Wick et al. 2014; Preusser et al. 2008; Chen et al. 2013).

Clinical trials referencedTrials and cohort studies (Stupp et al., NOA-04/NOA-08, Nordic trials, Perry et al.) relate MGMT status to treatment selection and outcomes.

Reliability notePCR-based testing reproducibility and alternative quantitative methods have been evaluated; validated laboratory methods are expected.

Definitions

MGMT promoter methylation — definition/clinical significance

DefinitionMGMT promoter methylation: Aberrant methylation of the MGMT gene promoter region leading to decreased MGMT protein expression and reduced DNA repair capacity, which can increase tumor susceptibility to alkylating chemotherapy.

PrevalenceApproximately 40–50% of glioblastoma multiforme tumors have MGMT promoter methylation.

Clinical implicationMethylation reduces MGMT-mediated repair of O6-guanine lesions, enhancing sensitivity to alkylating agents like temozolomide.

Temozolomide (TMZ) — definition/role

DefinitionTemozolomide (TMZ): An oral alkylating agent used as standard systemic chemotherapy for malignant gliomas; response to TMZ is associated with decreased MGMT activity in tumor tissue.

Role in therapyTMZ combined with radiotherapy is standard of care for most patients with newly diagnosed glioblastoma; TMZ alone or hypofractionated RT alone may be options in older patients depending on MGMT status and performance status.

Toxicity/considerationsTMZ is associated with modest increases in hematologic adverse events compared with radiotherapy alone; counseling on risks may affect treatment choice in patients with comorbidities.

MGMT methylation testing — assay description

Test descriptionAnalysis of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation from glioma tumor tissue using PCR-based or quantitative DNA methylation assays (e.g., methylation-specific PCR, restriction-coupled qPCR, multiplex ligation-dependent probe amplification).

Specimen and methodsTesting is performed on tumor tissue (formalin-fixed, paraffin-embedded) with PCR-based methods; formalin fixation can adversely affect bisulfite modification critical for some assays, and protocol variability affects reliability.

Laboratory expectationsValidated laboratory methods and documentation of tissue-based testing are expected due to reproducibility concerns; alternative quantitative approaches have been described for certain fixatives.

Background

Malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma, are aggressive primary brain tumors with a poor prognosis. Standard initial management typically includes maximal safe surgical resection followed by postoperative radiotherapy with concurrent and adjuvant chemotherapy such as temozolomide. MGMT promoter methylation refers to aberrant methylation of the MGMT gene promoter that reduces MGMT protein expression and impairs DNA repair of alkylation damage; tumors with MGMT promoter methylation are generally more responsive to alkylating agents like temozolomide. This biological association underlies the use of MGMT methylation testing to help inform first-line treatment decisions between radiotherapy and temozolomide-based chemotherapy in newly diagnosed high-grade gliomas and in select older patients.